Main Content

Adolescents Type 2 Diabetes

Study title

Phase 3, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of Exenatide once weekly in adolescents with type 2 diabetes

  • Principal Investigator: Naznin Dixit


This study seeks to evaluate the effect of an experimental drug in children and adolescents with type 2 diabetes mellitus.

Who can participate

Those eligible to participate in this study include:

  • Adolescents ages 10-17 diagnosed with type 2 mellitus

For more information

  • Deepali Bhatt
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson, MS 39216
    (601) 815-9481
  • IRB Number: 2017-0183